Biodexa Pharmaceuticals Plc Logo

Biodexa Pharmaceuticals Plc

Develops treatments for rare diseases, diabetes, and cancer using proprietary drug delivery tech.

BDRX | US

Overview

Corporate Details

ISIN(s):
GB00BNGF1L75 (+1 more)
LEI:
Country:
United States of America
Address:
1 CASPIAN POINT, CARDIFF
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Biodexa Pharmaceuticals Plc is a clinical-stage biotechnology company that develops treatments for diseases with high unmet medical needs. The company leverages proprietary drug delivery technologies to improve the bioavailability and distribution of therapeutic agents. Its lead development program, eRapa™, is a proprietary oral formulation of rapamycin (sirolimus) being evaluated in a Phase 3 trial for familial adenomatous polyposis (FAP), a rare genetic disorder. The company's pipeline also includes Tolimidone, a potential first-in-class lyn kinase inhibitor for type 1 diabetes, and treatments for primary and metastatic brain cancers.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Biodexa Pharmaceuticals Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Biodexa Pharmaceuticals Plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Biodexa Pharmaceuticals Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

SAWAI GROUP HOLDINGS Co., Ltd. Logo
A leading Japanese generic drug maker expanding into digital health and wellness solutions.
Japan
4887
Scandion Oncology A/S Logo
Biotech company in liquidation, formerly developing therapies to overcome cancer drug resistance.
Denmark
SCOL
Scholar Rock Holding Corp Logo
Biopharma developing medicines for neuromuscular diseases by targeting protein growth factors.
United States of America
SRRK
Scienture Holdings, Inc. Logo
Develops and commercializes specialty drugs for unmet medical needs, focusing on CNS disorders.
United States of America
SCNX
Scilex Holding Co Logo
Develops and commercializes non-opioid products for acute and chronic pain management.
United States of America
SCLX
Scinai Immunotherapeutics Ltd. Logo
Dual-model biopharma: developing NanoAbs for I&I and offering CDMO services.
United States of America
SCNI
SciSparc Ltd. Logo
Developing cannabinoid-based therapies for central nervous system (CNS) disorders.
United States of America
SPRC
Develops high-purity stem cell therapies for incurable immunological and inflammatory diseases.
South Korea
298060
scPharmaceuticals Inc. Logo
Commercializes subcutaneous drug-device therapies for at-home cardiorenal care.
United States of America
SCPH
SCYNEXIS INC Logo
Developing novel anti-fungal therapies for difficult-to-treat, drug-resistant infections.
United States of America
SCYX

Talk to a Data Expert

Have a question? We'll get back to you promptly.